Evaxion Biotech AS (EVAX) Stock Analysis

Evaxion Biotech AS (EVAX) is a publicly traded company in the HEALTHCARE sector. It trades at $3.75, carries a market capitalization of $33.36M. This page summarizes the public market data, fundamentals, and frequently asked questions for EVAX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.75
• Market Cap: $33.36M
• EPS: $-1.00
• 52-Week High: $12.15
• 52-Week Low: $2.07

About Evaxion Biotech AS

Evaxion Biotech AS (EVAX) is a pioneering clinical-stage biopharmaceutical company based in Hørsholm, Denmark, leveraging advanced artificial intelligence to drive innovation in immunotherapy. With a strategic focus on addressing unmet medical needs in oncology, bacterial diseases, and viral infections, the company utilizes its proprietary platform to identify and develop novel therapeutic candidates. As Evaxion progresses its diverse pipeline, it aims to transform treatment paradigms and enh...

GNG Research Analysis

GNG Research scores Evaxion Biotech AS (EVAX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for EVAX.

Frequently Asked Questions

Does EVAX pay dividends?

Evaxion Biotech AS (EVAX) does not currently pay a regular dividend.

What is EVAX's market cap?

Evaxion Biotech AS (EVAX) has a market capitalization of $33.36M with a current stock price of $3.75.